CPC A61K 31/352 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/127 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/136 (2013.01); A61K 31/353 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 38/005 (2013.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 31/404 (2013.01); A61K 31/44 (2013.01); A61P 9/00 (2018.01)] | 12 Claims |
1. A method for preventing, reducing, or eliminating cardiotoxicity induced by an anticancer agent in a subject, the method comprising administering to the subject an effective amount of a protective agent prior to or simultaneously with the anticancer agent, wherein the protective agent is myricetin or salt thereof, wherein the anticancer agent is a protein kinase inhibitor or a proteasome inhibitor, and wherein the administration of the protective agent provides an effective amount of myricetin or salt thereof in the subject, thereby preventing, reducing, or eliminating the cardiotoxicity induced by the anticancer agent.
|